View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2015	May 15, 2015
Document And Entity Information [Abstract]
Document Type	10-Q/A
Amendment Flag	true
AmendmentDescription	This Amendment No. 1 on Form 10-Q/A (the “Form 10-Q/A”) to the Quarterly Report on Form 10-Q for TapImmune Inc. (“we” or the “Company”) for the quarterly period ended March 31, 2015, initially filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2015 (the “Original Filing”), is being filed to restate accounting for the share purchase warrants and recording the fair value of the warrants under “Derivative liability- warrants” on its balance sheet with changes in the fair value over time reflected in the statements of operations as “Changes in fair value of derivative liabilities”. The restatement of the Company’s accounting for the share purchase warrants arose after a review by the Company’s management. As a result, the Board of Directors of the Company has determined that the Company’s previously issued consolidated unaudited financial statements and reports filed with the SEC for the quarterly period ended March 31, 2015 should not be relied upon. For a more detailed description of the effects of the restatement, see further discussion in Note 1A, “Amendment to Previously Reported Quarterly Financial Statements” to our consolidated financial statements included in Part I, Item 1 of this report. For the convenience of the reader, this Form 10-Q/A sets forth the Original Filings in their entirety. However, this Form 10-Q/A only amends and restates Items 1 and 2 of Part I of the Original Filing, in each case, solely as a result of, and to reflect, the restatement, and no other information in the Original Filing is amended hereby. The foregoing items have not been updated to reflect other events occurring after the Original Filings or to modify or update those disclosures affected by subsequent events. In addition, pursuant to the rules of the SEC, Item 6 of Part II of the Original Filings has been amended to contain currently dated certifications from the Company’s Chief Executive Officer and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, and are attached as Exhibits 31.1 and 32.1 to this report. We have also updated our financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibits 101. Except for the foregoing amended information, this Form 10-Q/A continues to speak as of the dates of the Original Filings, and the Company has not updated the disclosures contained herein to reflect events that occurred at a later date. Other events occurring after the filings of the Original Filings or other disclosures necessary to reflect subsequent events will be addressed in any reports filed with the SEC subsequent to the date of this filing.
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	TPIV
Entity Registrant Name	TAPIMMUNE INC
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		32,638,811

Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Current Assets
Cash	$ 1,453,505	$ 141,944
Prepaid expenses and deposits	82,504	82,504
Total Assets	1,536,009	224,448
Current Liabilities
Accounts payable and accrued liabilities	703,323	693,362
Research agreement obligations	492,365	492,365
Derivative liability - warrants	8,994,975	9,415
Promissory notes	52,942	52,942
Total Current Liabilities	10,243,605	1,248,084
Stockholders' Deficit
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 - 20,318,815)	32,639	20,319
Additional paid-in capital	85,269,526	85,265,776
Deficit accumulated during the development stage	(94,009,761)	(86,309,731)
Total Stockholders' Deficit	(8,707,596)	(1,023,636)
Total LIABILITIES AND STOCKHOLDERS' DEFICIT	1,536,009	224,448
Series A
Stockholders' Deficit
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Series B
Stockholders' Deficit
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:

Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2015	Dec. 31, 2014
Preferred stock par value	$ 0.001	$ 0.001
Convertible preferred stock	10,000,000	10,000,000
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000
Common stock shares issued	32,638,811	20,318,815
Common stock shares outstanding	32,638,811	20,318,815
Series A
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
Statements of Operations (Unaudited) - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
General and administrative	$ 418,786	$ 1,164,098
Research and development	609,378	22,500
Loss from Operations	(1,028,164)	(1,186,598)
Other Income (Expense)
Changes in fair value of derivative liabilities	327,440	(338,297)
Accretion of discount on convertible notes	0	(483,636)
Interest and financing charges	0	(35,269)
Loss on extinguishment of debt	0	(27,663,430)
Net Loss for the Period	(700,724)	(29,707,230)
Other comprehensive income
Foreign exchange translation adjustment	0	(1,249)
TOTAL COMPREHENSIVE LOSS	$ (700,724)	$ (29,708,479)
BASIC AND DILUTED NET LOSS PER SHARE	$ (0.03)	$ (3.89)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED	27,611,255	7,631,669

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - 3 months ended Mar. 31, 2015 - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss [Member]
Balance Amount at Dec. 31, 2014	$ (1,023,636)	$ 20,319	$ 85,265,776	$ (86,309,731)	$ 0
Balance, Shares at Dec. 31, 2014		20,318,816
Private placement (net of finders' fee of $140,000), Amount	2,326,014	$ 12,320	2,313,694
Private placement (net of finders' fee of $140,000), Shares		12,319,995
Fair value of warrants recognized as derivative liabilities	(9,313,000)		(2,313,694)	(6,999,306)
Stock- based compensation	3,750		3,750
Net loss	(700,724)			(700,724)
Balance Amount at Mar. 31, 2015	$ (8,707,596)	$ 32,639	$ 85,269,526	$ (94,009,761)	$ 0
Balance, Shares at Mar. 31, 2015		32,638,811

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2015 USD ($)
Statement of Stockholders' Equity [Abstract]
Finders fee	$ 140,000

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (700,724)	$ (29,707,230)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	(327,440)	338,297
Loss on extinguishment of debt	0	27,663,430
Non-cash interest and finance charges	0	483,636
Stock based compensation	3,750	690,000
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	9,961	158,913
NET CASH USED IN OPERATING ACTIVITIES	(1,014,453)	(372,954)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $140,000	2,326,014	0
Convertible note issuance	0	418,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,326,014	418,000
INCREASE IN CASH	1,311,561	45,046
CASH, BEGINNING OF PERIOD	141,944	48,589
CASH, END OF PERIOD	1,453,505	93,635
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES
Accounts payable settled in common stock	0	513,000
Fair value of issuance of warrants in January an March 2015 financing	9,313,000	0
Conversion of debt obligations into common stock
Accrued interest	0	476,000
Convertible notes payable	0	3,293,000
Loans payable, related party	0	42,000
Promissory notes, related party	0	210,000
Due to related parties	0	369,000
Fair value derivative liability - conversion opt at conversion	$ 0	$ 708,000

Statements of Cash Flows (Unaudited) (Parenthetical)	3 Months Ended
Statements of Cash Flows (Unaudited) (Parenthetical)	Mar. 31, 2015 USD ($)
Statement of Cash Flows [Abstract]
Issuance costs	$ 140,000

NATURE OF OPERATIONS	3 Months Ended
NATURE OF OPERATIONS	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1: NATURE OF OPERATIONS TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune’s approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

NOTE 1A: AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

The Company’s previously issued consolidated financial statements for the three months ended March 31, 2015 have been restated related to the Company’s accounting for share purchase warrants issued as part of two registered transactions in January 2015 and March 2015. Previously, the fair value of certain series of the share purchase warrants (Series B, B-1, C, C-1, D, D-1, E and E-1) was concluded by management to be classified within stockholders’ equity (deficit). The Company has reviewed the terms and conditions underlying its outstanding share purchase warrants and determined that the accounting for certain series of the warrants should be amended.

Management reviewed ASC 480-10 Distinguishing liabilities from equity and ASC 815-40 Contracts in an Entity’s Own Equity to arrive at this conclusion that the common stock purchase warrants should be classified as a liability, not equity, as the Company cannot control their ability to gross settle the financial instruments with registered securities.

The Company has restated its accounting for certain series of the share purchase warrants and recorded the fair value of the warrants under “Derivative liability- warrants” on its balance sheet with changes in the fair value over time reflected in the statements of operations as “Changes in fair value of derivative liabilities”.

As a result of these adjustments, net loss for the three months ended March 31, 2015 was reduced by $281,000. The Company has reported an amended net loss of $701,000 versus the previously reported net loss of approximately $982,000 for the three months ended March 31, 2015.

The following table summarizes the effect of the restatement on the consolidated statement of operations for the three months ended March 31, 2015:

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	March 31, 2015 (Unaudited)
	As Previously Reported			Adjustment			As Restated
ASSETS
Current Assets
Cash		1,453,505			—			1,453,505
Prepaid expenses and deposits		82,504			—			82,504

		1,536,009			—			1,536,009

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities		703,323			—			703,323
Research agreement obligations		492,365			—			492,365
Derivative liability – warrants		2,052,975			6,942,000			8,994,975
Promissory notes		52,942			—			52,942

		3,301,605			6,942,000			10,243,605

COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized:
Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815)		32,639			—			32,639
Additional paid-in capital		85,493,220			(223,694	)		85,269,526
Accumulated deficit		(87,291,455	)		(6,718,306	)		(94,009,761	)

		(1,765,596	)		(6,942,000	)		(8,707,596	)

		1,536,009			—			1,536,009

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Three Months Ended March 31, 2015
	As Previously Reported			Adjustment		As Restated
Operating expenses:
General and administrative		418,786			—		418,786
Research and development		609,378			—		609,378

Loss from Operations		(1,028,164	)		—		(1,028,164	)
Other Income (Expense)
Changes in fair value of derivative liabilities		46,440			281,000		327,440
Accretion of discount on convertible notes		—			—		—
Interest and financing charges		—			—		—
Loss on extinguishment of debt		—			—		—

Net Loss for the Period		(981,724	)		281,000		(700,724	)

Other comprehensive income
Foreign exchange translation adjustment		—			—		—

TOTAL COMPREHENSIVE LOSS		(981,724	)		281,000		(700,724	)

Basic and Diluted Net Loss per Share		(0.04	)		0.01		(0.03	)

Weighted Average Number of Common Shares Outstanding		27,611,255			27,611,255		27,611,255

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Three Months Ended March 31, 2015
	As Previously Reported			Adjustment			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(981,724	)		281,000			(700,724	)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities		(46,440	)		(281,000	)		(327,440	)
Loss on extinguishment of debt		—			—			—
Non-cash interest and finance charges		—			—			—
Stock based compensation		3,750			—			3,750
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		9,961			—			9,961

NET CASH USED IN OPERATING ACTIVITIES		(1,014,453	)		—			(1,014,453	)

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $140,000		2,326,014			—			2,326,014
Convertible note issuance		—			—			—

NET CASH PROVIDED BY FINANCING ACTIVITIES		2,326,014			—			2,326,014

INCREASE IN CASH		1,311,561			—			1,311,561
CASH, BEGINNING OF PERIOD		141,944			—			141,944

CASH, END OF PERIOD		1,453,505			—			1,453,505

BASIS OF PRESENTATION	3 Months Ended
BASIS OF PRESENTATION	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2: BASIS OF PRESENTATION The accompanying unaudited condensed financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of March 31, 2015, condensed consolidated statements of interim financials include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the Company’s annual report on Form 10-K.

LIQUIDITY AND FINANCIAL CONDITION	3 Months Ended
LIQUIDITY AND FINANCIAL CONDITION	Mar. 31, 2015
Text Block [Abstract]
LIQUIDITY AND FINANCIAL CONDITION	NOTE 3: LIQUIDITY AND FINANCIAL CONDITION The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. As of March 31, 2015, the Company had cash and cash equivalents of approximately $1,454,000. Historically, the Company has net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES	Mar. 31, 2015
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 4: SIGNIFICANT ACCOUNTING POLICIES There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 15, 2015. *Prior Period Reclassifications* Certain prior period amounts that were combined in the March 31, 2014 consolidated financial statements have been reclassified for comparability with the March 31, 2015 presentation. These reclassifications had no effect on previously reported net loss.

POTENTIALLY DILUTIVE SECURITIES

3 Months Ended

Mar. 31, 2015

Text Block [Abstract]

POTENTIALLY DILUTIVE SECURITIES

NOTE 5: POTENTIALLY DILUTIVE SECURITIES

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the three months ended March 31, 2015 and 2014, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:


	March 31,
	2015		2014
Common stock options		65,000		65,000
Common stock warrants - equity treatment		2,549,000		193,000
Common stock warrants - liability treatment		62,194,000		57,000
Convertible notes		—		15,000

Potentially dilutive securities		64,808,000		330,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION, AS RESTATED

3 Months Ended

Mar. 31, 2015

Text Block [Abstract]

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION, AS RESTATED

NOTE 6: DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION, AS RESTATED

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the three months ended 2015 and 2014 is as follows:


Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		0	%		0	%
Strike price	$	0.98		$	5.84
Volatility (annual)		158.00	%		159.00	%
Risk-free rate		1.00	%		0.65	%
Contractual term (years)		4.00			3.83

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants and Derivative liability – conversion option:


	As of March 31, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	8,995,000		—		—	$	8,995,000	$	8,995,000

Total	$	8,995,000		—		—	$	8,995,000	$	8,995,000


	As of December 31, 2014
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		—		—	$	9,000	$	9,000

Total	$	9,000		—		—	$	9,000	$	9,000

There were no transfers between Level 1, 2 or 3 during the three months ended March 31, 2015.

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2015:


	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the quarter		9,313,000
Change in fair value of warrant liability		(327,000	)

Balance – March 31, 2015	$	8,995,000

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

During 2014 the Company entered into numerous extinguishment agreements with various holders. As a result the derivative liability associated with the bifurcated conversion options were extinguished at the date of conversion and recorded in the loss on extinguishment in the Statement of Operations. The inputs utilized in the final mark to market were as follows:


Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		—	%		0	%
Strike price	$	—		$	1.03
Volatility (annual)		—	%		199.00	%
Risk-free rate		—	%		0.05	%
Contractual term (years)		—			0.24

Fair value of Conversion Option at extinguishment	$	—		$	708,000

PROMISSORY NOTES	3 Months Ended
PROMISSORY NOTES	Mar. 31, 2015
Text Block [Abstract]
PROMISSORY NOTES	NOTE 7: PROMISSORY NOTES, RELATED PARTY The Company has outstanding promissory notes in the amount of $52,942 (December 31, 2014 - $52,942), of which $23,000 of promissory notes are from an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms.

CAPITAL STOCK, AS RESTATED

3 Months Ended

Mar. 31, 2015

Text Block [Abstract]

CAPITAL STOCK, AS RESTATED

NOTE 8: CAPITAL STOCK, AS RESTATED

2015 Share Transactions

Private placements

In January, 2015, the Company entered into a Securities Purchase Agreement with certain investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 366,000 common shares with substantially the same terms as the January 2015 Warrants.

In March, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 125,000 common shares with substantially the same terms as the March 2015 Warrants.

Initial Fair Value of Warrants Issued

Pursuant to ASC 480-10 Distinguishing liabilities from equity and ASC 815-40 Contracts in an Entity’s Own Equity, the common stock purchase warrants are classified as a derivative liability as the Company cannot control their ability to gross settle the financial instruments with registered securities. The fair value of the warrants issued pursuant to the January and March 2015 stock purchase agreement was $9,313,000.

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of March 31, 2015 and changes during the period is presented below:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		62,090,975			1.03		3.96
Exercised		—			—		—
Extinguished or expired		(7,500	)		50.00		—

Balance, March 31, 2015		64,742,892		$	1.01		3.95

CONTINGENCIES AND COMMITMENTS	3 Months Ended
CONTINGENCIES AND COMMITMENTS	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES AND COMMITMENTS	NOTE 9: CONTINGENCIES AND COMMITMENTS Contingencies: *Consultant Litigation* In May 2012, the Company issued 112,000 post-consolidated shares of common stock to two consultants. The Company contested the validity of the services provided and initially was able to delay the sale of the contested shares. The Company was not successful in recovering the contested shares. A claim for alleged damages of approximately $362,000 plus costs by one of the consultants as a result of the contesting of the issuance of the shares was filed in the Supreme Court of New York. The claim was for damages on the difference between market price at the time the Company was able to delay the sale of his shares and the market price at the time of the sale of all of his shares. As the result of a judicial decision in New York the consultant received a bond payment of approximately $100,000 that the Company had used to secure a temporary restraining order against the issuance of stock to him. Following hearings at the International Arbitration Tribunal held in New York on May 13-16, 2014 the arbitrator ordered (on July 18, 2014) the consultant to pay Tapimmune $196,204 plus 9% interest from the date of the award. The Company is attempting to collect the award from Mr. Michael Gardner. On July 18, 2014, the International Center for Dispute Resolution International Arbitration Tribunal issued a Final Award in the matter of TapImmune Inc. vs. Michael Gardner awarding TapImmune $196,204 plus post-award interest at a rate of 9% per year. This award stemmed from the dispute discussed above with Mr. Gardner regarding the May 2012 consulting agreement. The arbitrator found that we were fraudulently induced into entering said agreement through “1) misrepresentations as to what he would or could do for the Company, including raising funds, and 2) omissions about his reputation and ability to obtain or assist in obtaining financing for TapImmune” among other reasons. We are attempting to collect the award from Mr. Gardner. *Vendor Litigation* One of our suppliers, Fischer Scientific was awarded a judgment against us for $51,000 which is equal to the amount owed to them and is currently accrued on the balance sheet. We intend on settling that matter in the second quarter of 2015.

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Mar. 31, 2015
Accounting Policies [Abstract]
Prior Period Reclassifications	*Prior Period Reclassifications* Certain prior period amounts that were combined in the March 31, 2014 consolidated financial statements have been reclassified for comparability with the March 31, 2015 presentation. These reclassifications had no effect on previously reported net loss.

AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS (Tables)

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Restatement of The Company's Consolidated Statements

The following table summarizes the effect of the restatement on the consolidated statement of operations for the three months ended March 31, 2015:

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	March 31, 2015 (Unaudited)
	As Previously Reported			Adjustment			As Restated
ASSETS
Current Assets
Cash		1,453,505			—			1,453,505
Prepaid expenses and deposits		82,504			—			82,504

		1,536,009			—			1,536,009

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities		703,323			—			703,323
Research agreement obligations		492,365			—			492,365
Derivative liability – warrants		2,052,975			6,942,000			8,994,975
Promissory notes		52,942			—			52,942

		3,301,605			6,942,000			10,243,605

COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized:
Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815)		32,639			—			32,639
Additional paid-in capital		85,493,220			(223,694	)		85,269,526
Accumulated deficit		(87,291,455	)		(6,718,306	)		(94,009,761	)

		(1,765,596	)		(6,942,000	)		(8,707,596	)

		1,536,009			—			1,536,009

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Three Months Ended March 31, 2015
	As Previously Reported			Adjustment		As Restated
Operating expenses:
General and administrative		418,786			—		418,786
Research and development		609,378			—		609,378

Loss from Operations		(1,028,164	)		—		(1,028,164	)
Other Income (Expense)
Changes in fair value of derivative liabilities		46,440			281,000		327,440
Accretion of discount on convertible notes		—			—		—
Interest and financing charges		—			—		—
Loss on extinguishment of debt		—			—		—

Net Loss for the Period		(981,724	)		281,000		(700,724	)

Other comprehensive income
Foreign exchange translation adjustment		—			—		—

TOTAL COMPREHENSIVE LOSS		(981,724	)		281,000		(700,724	)

Basic and Diluted Net Loss per Share		(0.04	)		0.01		(0.03	)

Weighted Average Number of Common Shares Outstanding		27,611,255			27,611,255		27,611,255

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Three Months Ended March 31, 2015
	As Previously Reported			Adjustment			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(981,724	)		281,000			(700,724	)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities		(46,440	)		(281,000	)		(327,440	)
Loss on extinguishment of debt		—			—			—
Non-cash interest and finance charges		—			—			—
Stock based compensation		3,750			—			3,750
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		9,961			—			9,961

NET CASH USED IN OPERATING ACTIVITIES		(1,014,453	)		—			(1,014,453	)

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $140,000		2,326,014			—			2,326,014
Convertible note issuance		—			—			—

NET CASH PROVIDED BY FINANCING ACTIVITIES		2,326,014			—			2,326,014

INCREASE IN CASH		1,311,561			—			1,311,561
CASH, BEGINNING OF PERIOD		141,944			—			141,944

CASH, END OF PERIOD		1,453,505			—			1,453,505

POTENTIALLY DILUTIVE SECURITIES (Tables)

3 Months Ended

Mar. 31, 2015

Text Block [Abstract]

POTENTIALLY DILUTIVE SECURITIES

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:


	March 31,
	2015		2014
Common stock options		65,000		65,000
Common stock warrants - equity treatment		2,549,000		193,000
Common stock warrants - liability treatment		62,194,000		57,000
Convertible notes		—		15,000

Potentially dilutive securities		64,808,000		330,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION, AS RESTATED (Tables)

3 Months Ended

Mar. 31, 2015

Text Block [Abstract]

Valuation Methodology


Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		0	%		0	%
Strike price	$	0.98		$	5.84
Volatility (annual)		158.00	%		159.00	%
Risk-free rate		1.00	%		0.65	%
Contractual term (years)		4.00			3.83

Financial Assets And Liabilities Measured At Fair Value On Recurring Basis


	As of March 31, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	8,995,000		—		—	$	8,995,000	$	8,995,000

Total	$	8,995,000		—		—	$	8,995,000	$	8,995,000


	As of December 31, 2014
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		—		—	$	9,000	$	9,000

Total	$	9,000		—		—	$	9,000	$	9,000

Measured at fair value

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2015:


	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the quarter		9,313,000
Change in fair value of warrant liability		(327,000	)

Balance – March 31, 2015	$	8,995,000

Numerous extinguishment agreements

The inputs utilized in the final mark to market were as follows:


Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		—	%		0	%
Strike price	$	—		$	1.03
Volatility (annual)		—	%		199.00	%
Risk-free rate		—	%		0.05	%
Contractual term (years)		—			0.24

Fair value of Conversion Option at extinguishment	$	—		$	708,000

CAPITAL STOCK, AS RESTATED (Tables)

3 Months Ended

Mar. 31, 2015

Text Block [Abstract]

Share purchase warrants

A summary of the Company’s share purchase warrants as of March 31, 2015 and changes during the period is presented below:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		62,090,975			1.03		3.96
Exercised		—			—		—
Extinguished or expired		(7,500	)		50.00		—

Balance, March 31, 2015		64,742,892		$	1.01		3.95

Amendment to Previously Reported Quarterly Financial Statements (Narrative) (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Loss for the Period	$ (700,724)	$ (29,707,230)
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Loss for the Period	(981,724)
Adjustments [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Loss for the Period	$ 281,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Restatements on The Company's Consolidated Balance Sheets (Detail) - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Current Assets
Cash	$ 1,453,505	$ 141,944	$ 93,635	$ 48,589
Prepaid expenses and deposits	82,504	82,504
Total Assets	1,536,009	224,448
Current Liabilities
Accounts payable and accrued liabilities	703,323	693,362
Research agreement obligations	492,365	492,365
Derivative liability - warrants	8,994,975	9,415
Promissory notes	52,942	52,942
Total Current Liabilities	10,243,605	1,248,084
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - shares authorized:
33 Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 - 20,318,815) 32,639 - 32,639	32,639	20,319
Additional paid-in capital	85,269,526	85,265,776
Accumulated deficit	(94,009,761)	(86,309,731)
Total Stockholders' Deficit	(8,707,596)	(1,023,636)
Total LIABILITIES AND STOCKHOLDERS' DEFICIT	1,536,009	224,448
As Previously Reported [Member]
Current Assets
Cash	1,453,505	$ 141,944
Prepaid expenses and deposits	82,504
Total Assets	1,536,009
Current Liabilities
Accounts payable and accrued liabilities	703,323
Research agreement obligations	492,365
Derivative liability - warrants	2,052,975
Promissory notes	52,942
Total Current Liabilities	3,301,605
Stockholders' Equity (Deficit)
Additional paid-in capital	85,493,220
Accumulated deficit	(87,291,455)
Total Stockholders' Deficit	(1,765,596)
Total LIABILITIES AND STOCKHOLDERS' DEFICIT	1,536,009
Adjustments [Member]
Current Liabilities
Derivative liability - warrants	6,942,000
Total Current Liabilities	6,942,000
Stockholders' Equity (Deficit)
Additional paid-in capital	(223,694)
Accumulated deficit	(6,718,306)
Total Stockholders' Deficit	$ (6,942,000)

Restatements on The Company's Consolidated Balance Sheets (Parenthetical) (Detail) - $ / shares	Mar. 31, 2015	Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001	$ 0.001
Convertible preferred stock	10,000,000	10,000,000
Common stock	$ 0.001	$ 0.001
Shares authorized	500,000,000
Shares issued	32,638,811	20,318,815
Outstanding	32,638,811	20,318,815
Series A
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

Restatements on The Company's Consolidated Statements of Operations and Comprehensive Loss (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
General and administrative	$ 418,786	$ 1,164,098
Research and development	609,378	22,500
Loss from Operations	(1,028,164)	(1,186,598)
Other Income (Expense)
Changes in fair value of derivative liabilities	327,440	(338,297)
Accretion of discount on convertible notes	0	483,636
Interest and financing charges	0	(35,269)
Loss on extinguishment of debt	0	(27,663,430)
Net Loss for the Period	(700,724)	(29,707,230)
Other comprehensive income
Foreign exchange translation adjustment	0	(1,249)
TOTAL COMPREHENSIVE LOSS	$ (700,724)	$ (29,708,479)
BASIC AND DILUTED NET LOSS PER SHARE	$ (0.03)	$ (3.89)
Weighted Average Number of Common Shares Outstanding	27,611,255	7,631,669
As Previously Reported [Member]
Operating expenses:
General and administrative	$ 418,786
Research and development	609,378
Loss from Operations	(1,028,164)
Other Income (Expense)
Changes in fair value of derivative liabilities	46,440
Accretion of discount on convertible notes	0
Interest and financing charges	0
Loss on extinguishment of debt	0
Net Loss for the Period	(981,724)
Other comprehensive income
Foreign exchange translation adjustment	0
TOTAL COMPREHENSIVE LOSS	$ (981,724)
BASIC AND DILUTED NET LOSS PER SHARE	$ (0.04)
Weighted Average Number of Common Shares Outstanding	27,611,255
Adjustments [Member]
Other Income (Expense)
Changes in fair value of derivative liabilities	$ 281,000
Accretion of discount on convertible notes	0
Interest and financing charges	0
Loss on extinguishment of debt	0
Net Loss for the Period	281,000
Other comprehensive income
Foreign exchange translation adjustment	0
TOTAL COMPREHENSIVE LOSS	$ 281,000
BASIC AND DILUTED NET LOSS PER SHARE	$ 0.01
Weighted Average Number of Common Shares Outstanding	27,611,255

Restatements on The Company's Consolidated Statements of Cash flow (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (700,724)	$ (29,707,230)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	(327,440)	338,297
Loss on extinguishment of debt	0	27,663,430
Non-cash interest and finance charges	0	483,636
Stock based compensation	3,750	690,000
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	9,961	158,913
NET CASH USED IN OPERATING ACTIVITIES	(1,014,453)	(372,954)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $140,000	2,326,014	0
Convertible note issuance	0	418,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,326,014	418,000
INCREASE IN CASH	1,311,561	45,046
CASH, BEGINNING OF PERIOD	141,944	48,589
CASH, END OF PERIOD	1,453,505	$ 93,635
As Previously Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	(981,724)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	(46,440)
Loss on extinguishment of debt	0
Non-cash interest and finance charges	0
Stock based compensation	3,750
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	9,961
NET CASH USED IN OPERATING ACTIVITIES	(1,014,453)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $140,000	2,326,014
Convertible note issuance	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,326,014
INCREASE IN CASH	1,311,561
CASH, BEGINNING OF PERIOD	141,944
CASH, END OF PERIOD	1,453,505
Adjustments [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	281,000
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	(281,000)
Loss on extinguishment of debt	0
Non-cash interest and finance charges	0
CASH FLOWS FROM FINANCING ACTIVITIES
Convertible note issuance	$ 0

Restatements on The Company's Consolidated Statements of Cash flow (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2015 USD ($)
Accounting Changes and Error Corrections [Abstract]
Issuance costs	$ 140,000

LIQUIDITY AND FINANCIAL CONDITION (Narrative) (Detail)	Mar. 31, 2015 USD ($)
Disclosure Disclosure Liquidity And Financial Condition Details Narrtive [Abstract]
Cash and cash equivalents	$ 1,454,000

POTENTIALLY DILUTIVE SECURITIES (Detail) - shares	3 Months Ended
POTENTIALLY DILUTIVE SECURITIES (Detail) - shares	Mar. 31, 2015	Mar. 31, 2014
Disclousure Potentially Dilutive Securities Details [Abstract]
Common stock options	65,000	65,000
Common stock warrants - equity treatment	2,549,000	193,000
Common stock warrants - liability treatment	62,194,000	57,000
Convertible notes		15,000
Potentially dilutive securities	64,808,000	330,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Strike price		$ 1.03
Share Purchase Warrants[Member]
Dividend yield (per share)	0.00%	0.00%
Strike price	$ 0.98	$ 5.84
Volatility (annual)	158.00%	159.00%
Risk-free rate	1.00%	0.65%
Contractual term (years)	4 years	3 years 9 months 29 days

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Details 1) (Detail) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Derivative liability - warrants	$ 8,995,000	$ 9,000
Total	8,995,000	9,000
Fair Value [Member]
Derivative liability - warrants	8,995,000
Total	8,995,000
Fair Value, Inputs, Level 1 [Member]
Derivative liability - warrants
Total
Fair Value, Inputs, Level 2 [Member]
Derivative liability - warrants
Total
Fair Value, Inputs, Level 3 [Member]
Derivative liability - warrants	8,995,000	9,000
Total	$ 8,995,000	9,000
Carrying Value [Member]
Derivative liability - warrants		9,000
Total		$ 9,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Details 2) (Detail)	3 Months Ended
	Mar. 31, 2015 USD ($)
Notes to Financial Statements
Balance - December 31, 2014	$ 9,000
Additions during the quarter	9,313,000
Change in fair value of warrant liability	(327,000)
Balance - March 31, 2015	$ 8,995,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Details 3) (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Notes To Financial Statements [Abstract]
Dividend yield (per share)	0.00%	0.00%
Strike price		$ 1.03
Volatility (annual)		199.00%
Risk-free rate		0.05%
Contractual term (years)		2 months 27 days
Fair value of Conversion Option at extinguishment	$ 0	$ 708,000

PROMISSORY NOTES, RELATED PARTY (Narrative) (Detail)	Dec. 31, 2014 USD ($)
Outstanding promissory notes in the amount	$ 52,942
Officer Director [Member]
Outstanding promissory notes in the amount	$ 23,000

CAPITAL STOCK (Narrative) (Detail)	1 Months Ended		3 Months Ended
CAPITAL STOCK (Narrative) (Detail)	Mar. 31, 2015 USD ($) $ / Equity shares	Jan. 31, 2015 USD ($) $ / shares $ / Equity shares	Mar. 31, 2015 USD ($) shares	Mar. 31, 2014 USD ($)
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Units issued	5,000,000
Sales price per unit \| $ / Equity	0.20
Aggregate purchase price \| $	$ 950,000
Finders fee and issuance costs \| $	$ 50,000
Number of common stock included in equity unit	1		1
Fair value of warrants \| $			$ 9,313,000	$ 0
Seriesa Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants	1		1
Series B Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants	1		1
Series C Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants	1		1
Series D Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants	1		1
Series E Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants	1		1
Subsequent Warrant Issuance [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of warrant or right, number of securities called by warrants or rights	125,000	366,000	125,000
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Units issued		7,320,000
Sales price per unit \| $ / Equity		0.20
Aggregate purchase price \| $		$ 1,250,000
Finders fee and issuance costs \| $		$ 214,000
Number of common stock included in equity unit		1
Private Placement [Member] \| Seriesa Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants		1
Exercise price of warrants \| $ / shares		$ 1.50
Warrant expiration period		5 years
Private Placement [Member] \| Series B Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants		1
Exercise price of warrants \| $ / shares		$ 0.40
Warrant expiration period		6 years
Private Placement [Member] \| Series C Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants		1
Exercise price of warrants \| $ / shares		$ 1.00
Warrant expiration period		5 years
Private Placement [Member] \| Series D Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants		1
Exercise price of warrants \| $ / shares		$ 0.75
Warrant expiration period		5 years
Private Placement [Member] \| Series E Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants		1
Exercise price of warrants \| $ / shares		$ 1.25
Warrant expiration period		5 years

CAPITAL STOCK (Detail)	3 Months Ended
CAPITAL STOCK (Detail)	Mar. 31, 2015 $ / shares shares
Number of Warrants
Balance, December 31, 2014 \| shares	2,659,417
Issued \| shares	62,090,975
Exercised \| shares	0
Extinguished or expired \| shares	(7,500)
Balance, March 31, 2015 \| shares	64,742,892
Weighted Average Exercise Price
Balance, December 31, 2014 \| $ / shares	$ 1.83
Issued \| $ / shares	1.03
Exercised \| $ / shares	0
Extinguished or expired \| $ / shares	50.00
Balance, March 31, 2015 \| $ / shares	$ 1.01
Weighted Average Remaining Life
Balance, December 31, 2014	4 years 1 month 24 days
Issued	3 years 11 months 16 days
Balance, March 31, 2015	3 years 11 months 12 days

CONTINGENCIES AND COMMITMENTS (Narrative) (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Number of post-consolidated shares of common stock	112,000
Claim for alleged damages	$ 362,000
Bond payment	100,000
Amount paid by consultant	$ 196,204
Interest paid by consultant	9.00%
Award amount		$ 196,204
Judgment award amount	$ 51,000